Physician profile
Berta Pita
NPI 1023365137
$1,265.05
in general payments reported to CMS, 2019-2025
24 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $96.59 · 2021: $313 · 2022: $46.47 · 2023: $79.44 · 2024: $177 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $235.19 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $175.30 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $119.40 | 2019-2025 | |
| Abbvie INC. | $87.77 | 2021 | |
| Hologic Sales and Service, LLC | $84.34 | 2023-2025 | Thinprep 2000 Processor, Aptima, Myosure Tissue Removal Device |
| Xeris Pharmaceuticals, INC. | $71.89 | 2021-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $61.16 | 2021-2023 | Arexvy, Shingrix |
| Pfizer INC. | $57.54 | 2019-2025 | |
| Corcept Therapeutics | $46.57 | 2021-2024 | Korlym |
| Tandem Diabetes Care, INC. | $39.33 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $35.29 | 2024 | Rybelsus, Ozempic |
| Amgen INC. | $33.86 | 2020-2021 | |
| Mannkind Corporation | $24.00 | 2025 | |
| Dexcom, INC. | $22.64 | 2025 | Dexcom G6 Transmitter |
| Ambu INC. | $21.96 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $20.03 | 2023 | |
| Sumitomo Pharma America, INC. | $19.95 | 2023 | Myfembree |
| E.R. Squibb & Sons, L.L.C. | $18.90 | 2021 | |
| Melinta Therapeutics, LLC | $17.73 | 2025 | Rezzayo |
| Insulet Corporation | $15.64 | 2020 | |
| Amneal Pharmaceuticals LLC | $14.98 | 2021 | |
| Lilly USA, LLC | $14.58 | 2025 | Mounjaro |
| Boston Scientific Corporation | $13.77 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Berta Pita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.